Literature DB >> 19908209

CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis.

Shinji Shimoda1, Kenichi Harada, Hiroaki Niiro, Akinobu Taketomi, Yoshihiko Maehara, Koichi Tsuneyama, Kentaro Kikuchi, Yasuni Nakanuma, Ian R Mackay, M Eric Gershwin, Koichi Akashi.   

Abstract

UNLABELLED: Improvements in the treatment of primary biliary cirrhosis (PBC) may depend upon dissection of mechanisms that determine recruitment of mononuclear cells to intralobular bile ducts, including the role of the chemokine-adhesion molecule CX3CL1 (fractalkine). We submit that there are unique interactions between intrahepatic biliary epithelial cells (BECs), endothelial cells (ECs), liver sinusoidal endothelial cells (LSECs), and liver-infiltrating mononuclear cells (LMCs), and that such interactions will in part dictate the biliary-specific inflammatory response. To address this, we studied fresh explanted livers from pretransplantation patients with PBC and with inflammatory liver disease due to viral infection (disease controls) and biopsy material from patients with a discrete liver tumor (normal controls). Using this clinical material, we isolated and stimulated BECs, ECs, LSECs, and LMCs with a panel of Toll-like receptor ligands. We also studied the interactions of these cell populations with LMCs with respect to adhesion capability and production of tumor necrosis factor alpha (TNF-alpha). Finally, we used fresh biopsy samples to evaluate mononuclear cells around intrahepatic biliary ductules using monoclonal antibodies specific to CD68 or CD154, markers for monocytes/macrophages, and activated T cells, respectively.
CONCLUSION: There are common properties of ECs, LSECs, and BECs, whether derived from PBC or viral hepatitis, but there are also significant differences, particularly in the potential in PBC for LMCs to adhere to ECs and BECs and to produce TNF-alpha; such properties were associated with augmented CX3CL1 production by BEC from PBC liver. The processes defined herein suggest potential novel biotherapies for biliary specific inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19908209      PMCID: PMC2911959          DOI: 10.1002/hep.23318

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

1.  Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance.

Authors:  A Limmer; J Ohl; C Kurts; H G Ljunggren; Y Reiss; M Groettrup; F Momburg; B Arnold; P A Knolle
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

2.  Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis.

Authors:  Bo Xu; Ulrika Broome; Mehmet Uzunel; Silvia Nava; Xupeng Ge; Makiko Kumagai-Braesch; Kjell Hultenby; Birger Christensson; Bo-Göran Ericzon; Jan Holgersson; Suchitra Sumitran-Holgersson
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

3.  Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis.

Authors:  S Shimoda; J Van de Water; A Ansari; M Nakamura; H Ishibashi; R L Coppel; J Lake; E B Keeffe; T E Roche; M E Gershwin
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

5.  CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells.

Authors:  S C Afford; J Ahmed-Choudhury; S Randhawa; C Russell; J Youster; H A Crosby; A Eliopoulos; S G Hubscher; L S Young; D H Adams
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

6.  A novel mechanism of liver allograft rejection facilitated by antibodies to liver sinusoidal endothelial cells.

Authors:  Suchitra Sumitran-Holgersson; Xupeng Ge; Azza Karrar; Bo Xu; Silvia Nava; Ulrika Broomé; Grzegorz Nowak; Bo-Göran Ericzon
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

7.  Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease.

Authors:  D G Binion; G A West; E E Volk; J A Drazba; N P Ziats; R E Petras; C Fiocchi
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

8.  Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans.

Authors:  Eva Efsen; Cecilia Grappone; Raffaella M S DeFranco; Stefano Milani; Roberto G Romanelli; Andrea Bonacchi; Alessandra Caligiuri; Paola Failli; Francesco Annunziato; Gabriella Pagliai; Massimo Pinzani; Giacomo Laffi; Paolo Gentilini; Fabio Marra
Journal:  J Hepatol       Date:  2002-07       Impact factor: 25.083

9.  Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.

Authors:  Bertus Eksteen; Allister J Grant; Alice Miles; Stuart M Curbishley; Patricia F Lalor; Stefan G Hübscher; Michael Briskin; Mike Salmon; David H Adams
Journal:  J Exp Med       Date:  2004-11-22       Impact factor: 14.307

10.  CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver.

Authors:  Katia Bourd-Boittin; Laetitia Basset; Dominique Bonnier; Annie L'helgoualc'h; Michel Samson; Nathalie Théret
Journal:  J Cell Mol Med       Date:  2009-05-11       Impact factor: 5.310

View more
  39 in total

1.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

Review 2.  Functional role of chemokines in liver disease models.

Authors:  Hacer Sahin; Christian Trautwein; Hermann E Wasmuth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 46.802

Review 3.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

4.  Chemokine-chemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis.

Authors:  Motoko Sasaki; Masami Miyakoshi; Yasunori Sato; Yasuni Nakanuma
Journal:  Dig Dis Sci       Date:  2013-11-02       Impact factor: 3.199

Review 5.  Immune Cell Trafficking to the Liver.

Authors:  Sulemon Chaudhry; Jean Emond; Adam Griesemer
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

6.  Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis.

Authors:  N Hashimoto; S Shimoda; H Kawanaka; K Tsuneyama; H Uehara; T Akahoshi; N Kinjo; A Taketomi; K Shirabe; K Akashi; A Lleo; A A Ansari; M E Gershwin; Y Maehara
Journal:  Clin Exp Immunol       Date:  2011-05-25       Impact factor: 4.330

7.  B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis.

Authors:  Yuki Moritoki; Masanobu Tsuda; Koichi Tsuneyama; Weici Zhang; Katsunori Yoshida; Zhe-Xiong Lian; Guo-Xiang Yang; William M Ridgway; Linda S Wicker; Aftab A Ansari; M Eric Gershwin
Journal:  Cell Immunol       Date:  2011-01-28       Impact factor: 4.868

Review 8.  Role of autoimmunity in primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 9.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

10.  RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.

Authors:  Yan-Li Hao; Zhao-Lian Bian; Lin-Ling Ju; Yuan Liu; Gang Qin
Journal:  Dig Dis Sci       Date:  2019-08-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.